Chemical Structure (Letrozole 01)
Chemical structure of letrozole, showing its molecular framework with two cyanophenyl groups connected to a triazole ring.*
Letrozole Tablet
Product Images NDC 51991-759
7 FDA label images from Breckenridge Pharmaceutical, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 51991-759). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Letrozole 02)
A Kaplan-Meier survival curve graph comparing Letrozole and Tamoxifen treatments over a period of 72 months. The solid line represents Letrozole, and the dashed line represents Tamoxifen. The y-axis shows survival probability from 0.0 to 1.0, and the x-axis shows time in months from 0 to 72. Patient risk numbers at various months are listed below the x-axis for both drugs.*
Figure 2 (Letrozole 03)
A progression-free survival graph comparing Letrozole tablets 2.5 mg and tamoxifen 20 mg over a period of 60 months. The y-axis indicates progression-free proportion, while the x-axis shows time in months. The graph depicts two survival curves illustrating the progression-free status over time for each treatment.*
Figure 3 (Letrozole 04)
A Kaplan-Meier survival curve chart comparing the proportion of patients alive over a 60-month period between two groups: one treated first with letrozole and the other with tamoxifen. The x-axis represents months (0 to 60), and the y-axis shows the fraction alive (0 to 1). Two survival curves are shown, one solid line for letrozole first and one dashed line for tamoxifen first.*
Figure 4 (Letrozole 05)
A Kaplan-Meier survival curve chart depicting time to progression in days for different treatment groups of Letrozole tablets. The x-axis shows time to progression in days, ranging from 0 to 1000, while the y-axis represents the proportion of patients without progression from 0.0 to 1.0. Three curves compare Letrozole 0.5 mg, Letrozole 2.5 mg, and MA treatment groups, showing their progression-free survival over time.*
Figure 5 (Letrozole 06)
A survival curve chart depicting time to progression in days on the x-axis and proportion on the y-axis. The chart compares three treatment groups: Letrozole Tablets 0.5 mg (solid line), Letrozole Tablets 2.5 mg (dotted line), and AG (dashed line), showing their progression over approximately 1000 days.*
Principal Display Panel (2.5 mg Tablet Bottle Label)
Letrozole tablets USP 2.5 mg oral dosage form label. The label states each film-coated tablet contains Letrozole USP 2.5 mg. It includes storage instructions (store at 25°C with excursions permitted between 15-30°C) and a warning to keep out of reach of children. The label shows the manufacturer as Natco Pharma Limited, India, and distributor as Breckenridge Pharmaceutical, Inc., Berlin, CT. The package contains 30 tablets and has an NDC barcode and a 2D barcode area marked.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
